Rezolute (RZLT) Stock Price, News & Analysis

Company Overview

Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic diseases. The company’s research is centered on conditions involving abnormal insulin signaling and glucose regulation, including rare disorders and complications associated with diabetes.

Rezolute’s lead investigational product is RZ358, a human monoclonal antibody designed to reduce the effects of excessive insulin activity. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas releases too much insulin and causes potentially dangerous episodes of low blood sugar. RZ358 has been evaluated in clinical studies involving children and adults with the condition.

The company has also advanced RZ402, an investigational oral plasma kallikrein inhibitor being developed for diabetic macular edema, a vision-threatening complication of diabetes. Rezolute’s pipeline reflects its broader goal of developing treatments that address significant unmet needs in metabolic and related diseases. The company is headquartered in Redwood City, California, and is led by President and Chief Executive Officer Nevan Elam.

Key Stats

• Today's Range: $3.90 to $4.33
• 50-Day Range: $3.84 to $5.09
• 52-Week Range: $1.07 to $11.46
• Volume: 2.12 million shs
• Average Volume: 1.89 million shs
• Market Capitalization: $377.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $11.22
• Consensus Rating: Moderate Buy

Rezolute Stock Analysis - MarketRank™

Rezolute scored higher than 67% of companies evaluated by MarketBeat, and ranked 251st out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rezolute has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on no strong buy ratings, 12 buy ratings, no hold ratings, and 2 sell ratings.

Upside Potential

Rezolute has a consensus price target of $11.22, representing about 187.7% upside from its current price of $3.90.

Amount of Analyst Coverage

Rezolute has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rezolute are expected to grow in the coming year, from ($0.63) to ($0.40) per share.

Price to Book Value per Share Ratio

Rezolute has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.28% of the float of Rezolute has been sold short.

Short Interest Ratio / Days to Cover

Rezolute has a short interest ratio ("days to cover") of 8.93.

Change versus previous month

Short interest in Rezolute has recently decreased by 0.59%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rezolute does not currently pay a dividend.

Dividend Growth

Rezolute does not have a long track record of dividend growth.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.25

News Sentiment

Rezolute has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Rezolute this week, compared to 4 articles on an average week.

Search Interest

4 people have searched for RZLT on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.

MarketBeat Follows

5 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rezolute insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.78% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 9/24/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RZLT
• CIK: 1509261
• Web: www.rezolutebio.com
• Phone: (650) 206-4507
• Fax: N/A
• Employees: 58
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Rezolute: $11.22
• High Price Target: $20.00
• Low Price Target: $6.00
• Potential Upside/Downside: +187.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.71
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.76)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$77.59 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.99%
• Return on Assets: -57.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.68
• Quick Ratio: 9.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.05 per share
• Price / Book: 3.71

Miscellaneous

• Outstanding Shares: 96,730,000
• Free Float: 82,432,000
• Market Cap: $377.25 million
• Optionable: Optionable
• Beta: 0.53